Treatment of bacterial pneumonia after influenza

流感后细菌性肺炎的治疗

基本信息

项目摘要

DESCRIPTION (provided by applicant): A synergistic interaction between influenza virus and bacteria contributes to excess mortality during influenza epidemics. Bacterial pneumonia after influenza infection typically presents at a more advanced stage, has complex features including multi-lobar involvement and bacteremia, and targets the frail and the elderly. For these reasons and because of the contribution of the virus itself to the pathogenesis, secondary bacterial pneumonia is more difficult to treat and the case fatality rate is higher. In addition, pre-clinical studies suggest that an over-exuberant host inflammatory response contributes to the severity of the illness and to treatment failures. The use of cell wall active antibiotics may be a contributing factor to these poor outcomes. The antibiotics most commonly used in clinical practice rapidly lyse organisms like Streptococcus pneumoniae and Staphylococcus aureus causing release of pathogen associated molecular patterns that act as triggers for inflammatory pathways, This problem may be exacerbated by the propensity of highly pathogenic influenza viruses such as the 1918 strain or the H5N1 strains currently infecting people in Asia and Europe to cause massive cytokine release. Since secondary bacterial infections account for a significant proportion of the deaths that occur during circulation of virulent strains, it is critical that we develop more effective treatment regimens before the next highly pathogenic influenza virus enters the population from avian sources or as a result of bioterrorism. We hypothesize that alternative treatment regimens, that do not lead to a robust host inflammatory response, will be more effective in the therapy of post-influenzal secondary bacterial pneumonia. This hypothesis will be tested in well described models of secondary pneumococcal and staphylococcal pneumonia. The goal of the proposed studies is to develop an effective treatment strategy for secondary bacterial pneumonia following influenza. The data generated by this work will provide a basis for educated treatment decisions in humans. PUBLIC HEALTH RELEVANCE: Secondary bacterial infections are a common cause of mortality during influenza epidemics, and are expected to be even more important during circulation of highly pathogenic influenza viruses such as pandemic strains or those released for the purposes of bioterrorism. Treatment of these infections is difficult and clinical failures are common for reasons that are at present unclear. The goal of the Proposed Studies is to generate information in a relevant pre-clinical model that will be immediately useful in planning for an influenza pandemic or bioterrorist event, as well as for annual influenza epidemics.
描述(由申请人提供):流感病毒和细菌之间的协同相互作用在流感流行期间导致过量死亡率。流感感染后的细菌性肺炎通常在更高级的阶段出现,具有复杂的特征,包括多叶涉及和细菌,靶向脆弱的和老年人。由于这些原因,并且由于病毒本身对发病机理的贡献,次生细菌性肺炎更难治疗,病例死亡率更高。此外,临床前研究表明,过度散发的宿主炎症反应有助于疾病的严重程度和治疗失败。细胞壁活性抗生素的使用可能是导致这些不良结果的一个因素。 The antibiotics most commonly used in clinical practice rapidly lyse organisms like Streptococcus pneumoniae and Staphylococcus aureus causing release of pathogen associated molecular patterns that act as triggers for inflammatory pathways, This problem may be exacerbated by the propensity of highly pathogenic influenza viruses such as the 1918 strain or the H5N1 strains currently infecting people in Asia and欧洲会引起大规模的细胞因子释放。由于继发性细菌感染构成了毒物循环过程中发生的很大一部分死亡,因此至关重要的是,在下一个高度致病的流感病毒之前,我们至关重要的是,我们必须开发更有效的治疗方案,从禽类来源或生物恐怖主义导致人群。我们假设不会导致强大的宿主炎症反应的替代治疗方案在治疗炎后次生细菌性肺炎方面更有效。该假设将在次要的肺炎球菌和葡萄球菌肺炎的模型中进行检验。拟议的研究的目的是为流感后的次生细菌性肺炎制定有效的治疗策略。这项工作产生的数据将为人类接受教育的治疗决策提供基础。公共卫生相关性:次生细菌感染是流感流行病期间死亡率的常见原因,预计在高度致病的流感病毒(例如大流行菌株或出于生物恐怖主义目的)的循环过程中更为重要。这些感染的治疗很困难,临床失败是目前尚不清楚的原因。拟议的研究的目的是在相关的临床前模型中生成信息,该模型将立即用于计划流感大流行或生物恐怖主义事件以及年度流感流行病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JONATHAN A MCCULLERS其他文献

JONATHAN A MCCULLERS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JONATHAN A MCCULLERS', 18)}}的其他基金

Incidence and etiology of pneumonia in children
儿童肺炎的发病率和病因
  • 批准号:
    8340463
  • 财政年份:
    2011
  • 资助金额:
    $ 25.85万
  • 项目类别:
Incidence and etiology of pneumonia in children
儿童肺炎的发病率和病因
  • 批准号:
    8725316
  • 财政年份:
    2011
  • 资助金额:
    $ 25.85万
  • 项目类别:
Incidence and etiology of pneumonia in children
儿童肺炎的发病率和病因
  • 批准号:
    8243295
  • 财政年份:
    2011
  • 资助金额:
    $ 25.85万
  • 项目类别:
Treatment of bacterial pneumonia after influenza
流感后细菌性肺炎的治疗
  • 批准号:
    7880623
  • 财政年份:
    2009
  • 资助金额:
    $ 25.85万
  • 项目类别:
Incidence and etiology of influenza associated pneumonia in hospitalized children
住院儿童流感相关性肺炎的发病率和病因
  • 批准号:
    7773919
  • 财政年份:
    2009
  • 资助金额:
    $ 25.85万
  • 项目类别:
Incidence and etiology of influenza associated pneumonia in hospitalized children
住院儿童流感相关性肺炎的发病率和病因
  • 批准号:
    7930729
  • 财政年份:
    2009
  • 资助金额:
    $ 25.85万
  • 项目类别:
2nd Co-infections Meeting
第二次合并感染会议
  • 批准号:
    7675107
  • 财政年份:
    2009
  • 资助金额:
    $ 25.85万
  • 项目类别:
Synergism Between Influenza Virus and Pneumococcus
流感病毒与肺炎球菌之间的协同作用
  • 批准号:
    6957297
  • 财政年份:
    2005
  • 资助金额:
    $ 25.85万
  • 项目类别:
Synergism Between Influenza Virus and Pneumococcus
流感病毒与肺炎球菌之间的协同作用
  • 批准号:
    7209728
  • 财政年份:
    2005
  • 资助金额:
    $ 25.85万
  • 项目类别:
Synergism Between Influenza Virus and Pneumococcus
流感病毒与肺炎球菌之间的协同作用
  • 批准号:
    7390388
  • 财政年份:
    2005
  • 资助金额:
    $ 25.85万
  • 项目类别:

相似国自然基金

签字注册会计师动态配置问题研究:基于临阵换师视角
  • 批准号:
    72362023
  • 批准年份:
    2023
  • 资助金额:
    28 万元
  • 项目类别:
    地区科学基金项目
全生命周期视域的会计师事务所分所一体化治理与审计风险控制研究
  • 批准号:
    72372064
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
会计师事务所数字化能力构建:动机、经济后果及作用机制
  • 批准号:
    72372028
  • 批准年份:
    2023
  • 资助金额:
    42.00 万元
  • 项目类别:
    面上项目
会计师事务所薪酬激励机制:理论框架、激励效应检验与优化重构
  • 批准号:
    72362001
  • 批准年份:
    2023
  • 资助金额:
    28.00 万元
  • 项目类别:
    地区科学基金项目
环境治理目标下的公司财务、会计和审计行为研究
  • 批准号:
    72332002
  • 批准年份:
    2023
  • 资助金额:
    165.00 万元
  • 项目类别:
    重点项目

相似海外基金

Alveolar responses to viral lung infection
肺泡对病毒性肺部感染的反应
  • 批准号:
    10503083
  • 财政年份:
    2022
  • 资助金额:
    $ 25.85万
  • 项目类别:
Alveolar responses to viral lung infection
肺泡对病毒性肺部感染的反应
  • 批准号:
    10650415
  • 财政年份:
    2022
  • 资助金额:
    $ 25.85万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10589966
  • 财政年份:
    2022
  • 资助金额:
    $ 25.85万
  • 项目类别:
Using CRISPR-Cas9 genetic abscission in vivo to study the role of GABA-A receptors of the thalamic reticular nucleus in regulating non-rapid-eye-movement sleep and drug induced sleep
利用体内CRISPR-Cas9基因分离研究丘脑网状核GABA-A受体对非快动眼睡眠和药物诱导睡眠的调节作用
  • 批准号:
    10552611
  • 财政年份:
    2020
  • 资助金额:
    $ 25.85万
  • 项目类别:
Using CRISPR-Cas9 genetic abscission in vivo to study the role of GABA-A receptors of the thalamic reticular nucleus in regulating non-rapid-eye-movement sleep and drug induced sleep
利用体内CRISPR-Cas9基因分离研究丘脑网状核GABA-A受体对非快动眼睡眠和药物诱导睡眠的调节作用
  • 批准号:
    10438528
  • 财政年份:
    2020
  • 资助金额:
    $ 25.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了